Penn Medicine Researchers Help Isolate Pathways of Resistance to Ibrutinib for Lymphoid Malignancies
Elenitoba-Johnson Lab et al. present new biomarker that identifies patients with aggressive lymphoma who don’t respond to precision therapy at American Society of Hematology Annual Meeting.
Read moreDr. Carl June Receives Leadership in Personalized Medicine Award
Personalized Medicine Coalition award recognizes new era in precision medicine with treatments characterized by ability to alter molecular characteristics of patients’ own cells.
Read moreCRISPR-engineered T cells in patients with refractory cancer
Genetically-edited immune cells can persist, thrive, and function months after a cancer patient receives them, according to new data published by researchers from the Abramson Cancer Center.
Center for Personalized Diagnostics Launches New Translocation Panel
Panel 2.0 includes 56 target genes and adds thyroid and sarcoma disease groups.
Read morePrecision Medicine with Dr. Babak Faryabi
Penn Medicine's Dr. Babak Faryabi presents his 2017 Precision Medicine Accelerator Fund project "AI-Driven Targeted Therapy in Acute Myeloid Leukemia."
Read morePrecision Medicine with Dr. Dan Herman
Penn Medicine's Dr. Daniel Herman presents his 2017 Precision Medicine Accelerator Fund project "Improving the Care of Secondary Hypertension: Automated Medical Record Screening."
Read more
